Johnson & Johnson halts mid-stage trial of experimental eczema drug [CNBC]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: CNBC
Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate to severe atopic dermatitis after it failed to meet efficacy goals in an interim analysis. The drug, JNJ-5939, was being tested in patients with atopic dermatitis, or eczema, a skin condition that causes inflammation, redness and intense itching. The drug was well-tolerated but did not meet the “high-bar” efficacy required to advance development, the company said. Johnson & Johnson said it remains committed to developing treatments for atopic dermatitis, a chronic condition that affects more than 100 million people worldwide. The company is developing other experimental treatments for atopic dermatitis, including bispecific antibodies NM26, PX128 and PX130, as well as an oral STAT6 inhibitor, KP-723. Eczema has multiple approved treatments, such as Sanofi and Regeneron's Dupixent, AbbVie's Rinvoq, Pfizer's Cibinqo, Eli Lilly's Ebglyss, as well as some
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Business Insider staff share their favorite books of 2025 [Business Insider]Business Insider
- Is Johnson & Johnson's (JNJ) Recent Rally Still Leaving the Stock Undervalued? [Yahoo! Finance]Yahoo! Finance
- Here's Why Johnson & Johnson (JNJ) Surged in Q3 [Yahoo! Finance]Yahoo! Finance
- $1.5 billion Baltimore verdict holds Johnson & Johnson liable over baby powder [CBS News]CBS News
- J&J Ordered to Pay Over $1.5 Billion in Talc Lawsuit [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 10/14/25 - Beat
JNJ
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- JNJ's page on the SEC website